Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01792050 · ClinicalTrials.gov registry record · Phase 2
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase 2 study, sponsored by NewLink Genetics Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 169
- Enrollment target
NCT01792050: Completed Phase 2 study, sponsored by NewLink Genetics Corporation.
NCT01792050 is a Phase 2 study that has completed, run by NewLink Genetics Corporation. The registered enrollment target is 169 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (27% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01792050, a Phase 2 study, has completed, sponsored by NewLink Genetics Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 169 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the effects, good and/or bad, of standard of care therapy (docetaxel or paclitaxel) with or without the addition of 1-Methyl-D-tryptophan (referred to as indoximod) an experimental drug to find out which treatment is better.
Primary Outcome
The primary objective of this phase 2 study is the progression free survival of docetaxel or paclitaxel in combination with indoximod compared to docetaxel or paclitaxel plus placebo in metastatic breast cancer.
Interventions
- DRUG Docetaxel
- OTHER Placebo
- DRUG Paclitaxel
- DRUG Indoximod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169 participants |
| Start Date | 2013-02 |
| Est. Completion | 2017-07-07 |
| Phase | Phase 2 |
What the finished NCT01792050 record still lists
NCT01792050 is an interventional study that assigns participants to a tested intervention. The registered 169 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (27% higher).
The record links to 0 conditions, and to 4 interventions - of which Docetaxel is the first listed.
NCT01792050 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01792050 about?
NCT01792050 is a clinical study titled "Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer". The purpose of this study is to compare the effects, good and/or bad, of standard of care therapy (docetaxel or paclitaxel) with or without the addition of 1-Methyl-D-tryptophan (referred to as indoximod) an experimental drug to find out which treatment is better.
What is the current status of trial NCT01792050?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 169 participants. The study started on 2013-02. Estimated completion is 2017-07-07.
What interventions are being tested in trial NCT01792050?
The interventions under investigation include: Docetaxel (DRUG), Placebo (OTHER), Paclitaxel (DRUG), Indoximod (DRUG).
Who is sponsoring clinical trial NCT01792050?
This trial is sponsored by NewLink Genetics Corporation, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01792050's enrollment target sits among peer trials
169 403rd of 2000 higher than 1,598 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06191484 · 169 participants · NA
Risk and Resilience to Suicide Following Late-Life Spousal Bereavement
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia